Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
EL

NASDAQ · ELAB

PMGC Holdings Inc.

Healthcare · Biotechnology

$3.27

Up+$0.00 (+0.00%)

Updated Oct 7, 2026, 7:04 AM

SID Score

3.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.71M
P/E ratio
-0.52
Dividend yield
0.00%
52-week range
$0.84 – $267.12
Volume
14.66K
Avg. volume
556.88K

Price performance · ELAB

ELAB price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

ELAB closed at $3.27 after 21 trading sessions, down 32.58% for the selected period.

Last close
$3.27
Period change
-32.58%
Period low
$3.23
Period high
$4.85
Daily close
View OHLC price history
ELAB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$3.23$3.30$3.08$3.2714.66K
Oct 5, 2026$3.30$3.36$3.0601$3.2741.54K
Oct 2, 2026$3.35$3.45$3.20$3.3621.21K
Oct 1, 2026$3.54$3.54$2.585$3.225181.95K
Sep 30, 2026$3.75$3.75$3.47$3.5441.99K
Sep 29, 2026$4.66$4.97$3.40$3.67205.66K
Sep 28, 2026$4.54$5.5599$4.53$4.78252.89K
Sep 25, 2026$4.46$4.60$4.35$4.578.84K
Sep 24, 2026$4.57$4.71$4.43$4.5211.85K
Sep 23, 2026$4.34$4.64$4.32$4.5340.04K
Sep 22, 2026$4.27$4.5239$4.13$4.2628.62K
Sep 21, 2026$4.68$4.74$4.35$4.4221.9K
Sep 18, 2026$4.56$5.07$4.56$4.78135.57K
Sep 17, 2026$4.76$4.7825$4.60$4.728.33K
Sep 16, 2026$4.80$4.8799$4.56$4.7718.2K
Sep 15, 2026$4.64$4.90$4.55$4.8235.51K
Sep 14, 2026$4.48$4.82$4.41$4.6221.19K
Sep 11, 2026$4.73$4.7394$4.4006$4.5211.4K
Sep 10, 2026$4.62$4.80$4.531$4.6017.84K
Sep 9, 2026$4.80$4.8946$4.60$4.6229.68K
Sep 8, 2026$5.21$5.35$4.8201$4.8530.18K

Latest ELAB news

The latest Smart Investors Daily articles mentioning ELAB.

Stock researchCompany · Overview

ELAB research

Overview

Company profile and research snapshot.

Company profile

PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 1, 2026

PMGC Holdings (Nasdaq: ELAB) Announces Completion of $100 Million SPAC IPO, Launching NorthStrive Acquisition Corp. I (Nasdaq: NSAI) as First in Planned SPAC Sponsorship Franchise to Expand M&A Strategy

PMGC's first sponsored SPAC adds a public-market acquisition vehicle to the holding company, targeting aerospace and defense, industrial technology, and critical supply chain manufacturersSponsor position of approximately 2.7 million shares, or roughly 21.4% of NorthStrive Acquisition Corp I.'s Class A shares on an as-converted basis, aligns PMGC with value created through a future business combination NEWPORT BEACH, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“P

Yahoo · Sep 1, 2026

NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications

Building on positive Phase III results from the parties' AI-driven drug discovery program, the six-month Expansion Program will narrow the four validated compounds toward a nominated lead and designated backup. The Amendment also strengthens the exclusive Cardiac Disease and Obesity field of use and adds a right of first refusal across the broader cardiometabolic field. NEWPORT BEACH, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. ("NorthStrive Biosciences"), a subsidiar

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By